​

Allogene Therapeutics (ALLO) Revenue & Revenue Breakdown

OverviewForecastOwnershipFinancialsChartTranscripts

Allogene Therapeutics Revenue Highlights

Latest Revenue (Y)

$22.00K

0

Main Segment (Y)

License

Allogene Therapeutics Revenue by Period

Allogene Therapeutics Revenue by Year

DateRevenueChange
2024-12-31$22.00K-76.84%
2023-12-31$95.00K-60.91%
2022-12-31$243.00K-99.37%
2021-12-31$38.49M100.00%
2020-12-31-100.00%
2019-12-31-100.00%
2018-12-31-100.00%
2017-12-31--

Allogene Therapeutics generated $22.00K in revenue during NA 2024, up -76.84% compared to the previous quarter, and up Infinity% compared to the same period a year ago.

Allogene Therapeutics Revenue by Quarter

DateRevenueChange
2024-09-30-100.00%
2024-06-30--100.00%
2024-03-31$22.00K4.76%
2023-12-31$21.00K-51.16%
2023-09-30$43.00K-2.27%
2023-06-30$44.00K-15.38%
2023-03-31$52.00K10.64%
2022-12-31$47.00K-4.08%
2022-09-30$49.00K-43.02%
2022-06-30$86.00K40.98%
2022-03-31$61.00K19.61%
2021-12-31$51.00K4.08%
2021-09-30$49.00K11.36%
2021-06-30$44.00K-99.89%
2021-03-31$38.34M100.00%
2020-12-31-100.00%
2020-09-30-100.00%
2020-06-30-100.00%
2020-03-31-100.00%
2019-12-31-100.00%
2019-09-30-100.00%
2019-06-30-100.00%
2019-03-31-100.00%
2018-12-31-100.00%
2018-09-30-100.00%
2018-06-30-100.00%
2018-03-31-100.00%
2017-12-31--

Allogene Therapeutics generated - in revenue during Q3 2024, up 100.00% compared to the previous quarter, and up 0.00% compared to the same period a year ago.

Allogene Therapeutics Revenue Breakdown

Allogene Therapeutics Revenue Breakdown by Product

Annual Revenue by Product

Product/ServiceDec 24
License$4.60M

Allogene Therapeutics's latest annual revenue breakdown by segment (product or service), as of Dec 24: License (100.00%).

Allogene Therapeutics Peer Comparison by Revenue

TickerCompanyLast Year RevenueLast Quarter Revenue
BPMCBlueprint Medicines$508.82M$128.18M
HRTXHeron Therapeutics$144.28M$36.02M
SGMOSangamo Therapeutics$57.80M$356.00K
ITOSiTeos Therapeutics$35.00M$35.00M
VERVVerve Therapeutics$32.33M$6.87M
RLAYRelay Therapeutics$10.01M-
IPSCCentury Therapeutics$6.59M$791.00K
PRMEPrime Medicine$2.98M$39.31M
ALLOAllogene Therapeutics$22.00K-
NTLAIntellia Therapeutics-$9.11M
EDITEditas Medicine--
ANNXAnnexon--
SANASana Bio--
CRBUCaribou Biosciences-$3.46M
BEAMBeam Therapeutics-$14.27M

ALLO Revenue FAQ

What is Allogene Therapeutics’s yearly revenue?

Allogene Therapeutics's yearly revenue for 2024 was $22K, representing a decrease of -76.84% compared to 2023. The company's yearly revenue for 2023 was $95K, representing a decrease of -60.91% compared to 2022. ALLO's yearly revenue for 2022 was $243K, representing a decrease of -99.37% compared to 2021.

What is Allogene Therapeutics’s quarterly revenue?

Allogene Therapeutics's quarterly revenue for Q3 2024 was $0, a 100.00% increase from the previous quarter (Q2 2024), and a -100.00% decrease year-over-year (Q3 2023). The company's quarterly revenue for Q2 2024 was $0, a -100.00% decrease from the previous quarter (Q1 2024), and a -100.00% decrease year-over-year (Q2 2023). ALLO's quarterly revenue for Q1 2024 was $22K, a 4.76% increase from the previous quarter (Q4 2023), and a -57.69% decrease year-over-year (Q1 2023).

What is Allogene Therapeutics’s revenue growth rate?

Allogene Therapeutics's revenue growth rate for the last 3 years (2022-2024) was -90.95%, and for the last 5 years (2020-2024) was 0%.

What are Allogene Therapeutics’s revenue streams?

Allogene Therapeutics's revenue streams in c 24 are License

What is Allogene Therapeutics’s main source of revenue?

For the fiscal year ending Dec 24, the largest source of revenue of Allogene Therapeutics was License. This segment made a revenue of $4.6M, representing 100.00% of the company's total revenue.